AZD6482

製品コードS1462 別名:KIN-193

AZD6482化学構造

分子量(MW):408.45

AZD6482は一種のPI3Kβ阻害剤で、無細胞試験でIC50値が10 nMで、PI3Kβに作用する選択性はPI3Kδ、PI3KαとPI3Kγに作用する選択性より8倍、87倍、109倍それぞれに高くなります。臨床1期。

サイズ 価格(税別) 在庫  
JPY 28220.00 あり
JPY 53120.00 あり
JPY 161020.00 あり

カスタマーフィードバック(4)

  • Collagen-embedded melanoma spheroids were treated for 72 h with SGI-1776 [5 μM] or AZD6482 [10 μM] as single agents or in combination before staining for live (green) and dead (red) cells. Experiments were conducted in triplicate and representative images are shown. Scale bar represents 150 microns.

    Oncotarget, 2016, 7(34):54897-54912. AZD6482 purchased from Selleck.

    Cells treated with either control or INPP4B siRNA and following a 1-hour treatment with either DMSO or 1 mmol/L inhibitor; pPRAS40T246 and total PRAS40 were run on a separate blot for which the bottom Ku-86 panel is the loading control(pan-PI3Ki: GDC-0941, PI3K-ai: BYL719,PI3K-bi: AZD6482)

    Mol Cancer Res, 2017. AZD6482 purchased from Selleck.

  • Dose response curve of compound on melanoma cell lines.  Compound was dissolved in DMSO, added in a 5-fold dilution series, starting with 10 μM, and incubated for 72 hours.  Fluorescence was measured after 8 hours incubation in resazurin.  Data was normalized to DMSO (maximal viability) and Doxorubicin (minimum viability).

    One customer. AZD6482 purchased from Selleck.

    After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of AZD6482 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. AZD6482 purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 AZD6482は一種のPI3Kβ阻害剤で、無細胞試験でIC50値が10 nMで、PI3Kβに作用する選択性はPI3Kδ、PI3KαとPI3Kγに作用する選択性より8倍、87倍、109倍それぞれに高くなります。臨床1期。
ターゲット
PI3Kβ [1]
(Cell-free assay)
PI3Kδ [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
PI3Kα [1]
(Cell-free assay)
10 nM 80 nM 420 nM 870 nM
体外試験

AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human RXF393 cell M2LnRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{XnW2lvcGmkaYTpc44hd2ZiaIXtZY4hWliIM{mzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTF3NDFOwG0> NIfseJdUSU6JRWK=
human SW982 cell M4rEVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYP3W3JlUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODN3OESg{txO NHLaOmRUSU6JRWK=
human MAD-MB-468 cells M2L1SWZ2dmO2aX;uJIF{e2G7 M{XWZ2lvcGmkaYTpc44hd2ZiUFmzT4JmfGFiaX6gbJVu[W5iTVHEMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOnckS3N{BCc3RicHjvd5Bpd3K7bHH0bY9vKGK7IHPlcIx2dGG{IIDveIVv[3liYYPzZZktKEmFNUC9NE4xPCEQvF2= NUnxNmtsOjR7OUK4O|Q>
human KURAMOCHI cell M1TVe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHTi[XhKdmirYnn0bY9vKG:oIHj1cYFvKEuXUlHNU2NJUSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUC1NUDPxE1? NVnPWIplW0GQR1XS
human A498 cell NYrXNW9bT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIHHNVFKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyPzl3IN88US=> MUTTRW5ITVJ?
human YT cell MmjHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlPyTY5pcWKrdHnvckBw\iCqdX3hckB[XCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUKwOlYh|ryP MYTTRW5ITVJ?
human VMRC-RCZ cell M1;UT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mme2TY5pcWKrdHnvckBw\iCqdX3hckBXVVKFLWLDXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTR6OUig{txO NVTNR5o2W0GQR1XS
human MDA-MB-415 cell NVT2V3J1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20NVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4N{OyJO69VQ>? M4HOTXNCVkeHUh?=
human J82 cell MnjVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU\tdmE2UW6qaXLpeIlwdiCxZjDoeY1idiCMOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4Pzd7IN88US=> Mn7KV2FPT0WU
human SW1710 cell MoPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1PHWGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42Ojl{IN88US=> MmDUV2FPT0WU
human T47D cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHIZmVKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{OjdizszN NGPjUWpUSU6JRWK=
human SU-DHL-1 cell MmLQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFz1VIFKdmirYnn0bY9vKG:oIHj1cYFvKFOXLVTIUE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53NkixN{DPxE1? M4W4RXNCVkeHUh?=
human BT-20 cell M1rqTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MojLTY5pcWKrdHnvckBw\iCqdX3hckBDXC1{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVkzOjJizszN MUDTRW5ITVJ?
human OS-RC-2 cell MnXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlSzTY5pcWKrdHnvckBw\iCqdX3hckBQWy2UQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43OjN6ODFOwG0> M2fvZXNCVkeHUh?=
human RPMI-6666 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnG5TY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLU[2OlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjZ2M{e5JO69VQ>? NUT4epM5W0GQR1XS
human OVCAR-3 cell MoTZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWDZPXFyUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC54N{m0OkDPxE1? NUD3N5VPW0GQR1XS
human NALM-6 cell M3;hXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5CVE1vNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|A1PjVizszN MoXIV2FPT0WU
human RS4-11 cell M1z2WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjLc|V7UW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd|OEC2JO69VQ>? NH60TWtUSU6JRWK=
human SK-MES-1 cell MmHtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QDl4NzFOwG0> NGK2XFhUSU6JRWK=
human ES7 cell M{iwOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXrJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEGyPFYh|ryP Ml2zV2FPT0WU
human NCI-H2342 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYrybpBWUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0Nlk1KM7:TR?= M{\SPXNCVkeHUh?=
human SCC-9 cell M33ab2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWq4bJF7UW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDV5NzFOwG0> NGLnNIFUSU6JRWK=
human EW-7 cell NGPafGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFHJUlFKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3OzV4IN88US=> MVLTRW5ITVJ?
human HH cell NHjxOpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHfCO4pKdmirYnn0bY9vKG:oIHj1cYFvKEiKIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OlIzOiEQvF2= M1S2bHNCVkeHUh?=
human A427 cell NHO1UWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjxVm9pUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QTVyNTFOwG0> NX3BdVdqW0GQR1XS
human Daudi cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;BUoZWUW6qaXLpeIlwdiCxZjDoeY1idiCGYYXkbUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODZ6OEig{txO M2XjR3NCVkeHUh?=
human P30-OHK cell NH\QZZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA4OTN6IN88US=> NXjXOlFSW0GQR1XS
human HGC-27 cell M1m4WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn\1TY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVEvOThzNjFOwG0> MknEV2FPT0WU
human CAMA-1 cell NWO2WJNzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEH1cmJKdmirYnn0bY9vKG:oIHj1cYFvKEODTVGtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjByMTFOwG0> MWTTRW5ITVJ?
human SK-OV-3 cell NXSzXVRJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NU\6clBJUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{MES0OEDPxE1? MmH4V2FPT0WU
human NCI-H1048 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC0PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjJ3N{mg{txO M{HCZ3NCVkeHUh?=
human MEL-HO cell NYq2TWs{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2Lu[GlvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPDJ|ODFOwG0> M4TP[3NCVkeHUh?=
human NKM-1 cell NE\HfYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGjnNo9KdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zQDZ|NjFOwG0> NWPhN|h7W0GQR1XS
human NCI-H650 cel NX7vdWUxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjoTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzByN{[g{txO NI[zNFJUSU6JRWK=
human HAL-01 cell NHvCXpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhCVC1yMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|AyPzVizszN NXzKVpBIW0GQR1XS
human 786-0 cell NIq3SmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1ezZmlvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMyOjh|IN88US=> MUXTRW5ITVJ?
human GI-1 cell M1H0XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkOxPFA5KM7:TR?= NVPRWo97W0GQR1XS
human Becker cell NWTFV|NRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnT0TY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM3OzF3IN88US=> MlXaV2FPT0WU
human CCF-STTG1 cell M3P5bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWXJcohq[mm2aX;uJI9nKGi3bXHuJGNETi2VVGTHNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDJ3MkWg{txO MXLTRW5ITVJ?
human MC116 cell M37BbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfTT3pKdmirYnn0bY9vKG:oIHj1cYFvKE2FMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjF{MjFOwG0> NEfkSYRUSU6JRWK=
human MDA-MB-468 cell NULaOlNLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTlT4ZPUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuPDZ6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61N|c{PiEQvF2= MU\TRW5ITVJ?
human NB12 cell NVXBUnJTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlvoTY5pcWKrdHnvckBw\iCqdX3hckBPSjF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61OFg1OiEQvF2= NV\jXJRQW0GQR1XS
human LXF-289 cell NGf2OnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLpOo83UW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53NUGwOEDPxE1? M13x[HNCVkeHUh?=
human MFE-296 cell MnPGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU3QDN4IN88US=> M1HkfXNCVkeHUh?=
human SNU-423 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2r4WWlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUSyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTdzOUKg{txO NV7OVFdzW0GQR1XS
human NCI-H2291 cell MmnmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkK5NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTd4MTFOwG0> M{O0O3NCVkeHUh?=
human OCUB-M cell NH7BRpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\5Z2lvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42QDNzNDFOwG0> NV\Fd41{W0GQR1XS
human KU812 cell M3PEUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITBcm1KdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42QTZ{ODFOwG0> MXvTRW5ITVJ?
human HuO9 cell M2WwUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXH2dZpwUW6qaXLpeIlwdiCxZjDoeY1idiCKdV:5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OTJ6IN88US=> MUTTRW5ITVJ?
human 639-V cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTXTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlMyPDRizszN MUXTRW5ITVJ?
human HCC70 cell M{nWb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhESzdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62OlE1PiEQvF2= MVXTRW5ITVJ?
human SNB75 cell M4nLd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2XhU2lvcGmkaYTpc44hd2ZiaIXtZY4hW06EN{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY3PTB6IN88US=> NUG1UXdTW0GQR1XS
human D-336MG cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHnbmxKdmirYnn0bY9vKG:oIHj1cYFvKERvM{O2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ4OEig{txO M3nreXNCVkeHUh?=
human LoVo cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGjOe2NKdmirYnn0bY9vKG:oIHj1cYFvKEyxVn:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc{QDJ3IN88US=> M2[0WXNCVkeHUh?=
human EB2 cell NYSycpRYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVn4R5RtUW6qaXLpeIlwdiCxZjDoeY1idiCHQkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc2ODF7IN88US=> MV7TRW5ITVJ?
human HSC-2 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHQTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|U4OjdizszN M{XvS3NCVkeHUh?=
human D-542MG cell NYrzVIZHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUW2dWhRUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW0Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NUC3O{DPxE1? NGnqOYFUSU6JRWK=
human COLO-684 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVvJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zODB|MjFOwG0> NVGwTWpsW0GQR1XS
human GDM-1 cell M3TEVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvUTY5pcWKrdHnvckBw\iCqdX3hckBITE1vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlQzODZizszN MYnTRW5ITVJ?
human SW1088 cell NUn2S|ViT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFgyPDNizszN M3q2cHNCVkeHUh?=
human SF295 cell NGPx[2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvKc|NKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44Pjl3NTFOwG0> NUjCSnRHW0GQR1XS
human NCI-H2030 cell NH63V29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPSSHVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUCyPFgh|ryP MkP6V2FPT0WU
human NCI-H1755 cell NGjuSZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjdyNkOg{txO NUHZSYtmW0GQR1XS
human MDA-MB-361 cell Mn22S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV{N{C5JO69VQ>? MWfTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Assay of PI3K enzyme inhibition:

The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
細胞試験: [1]
+ 展開
  • 細胞株: Human platelet pellet
  • 濃度: 0–60 nM, dissolved in DMSO
  • 反応時間: 5 min
  • 実験の流れ: For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 1015/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (200.75 mM)
Ethanol 10 mg/mL (24.48 mM)
Water Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 408.45
化学式

C22H24N4O4

CAS No. 1173900-33-8
保管
別名 KIN-193

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00853450 Completed Antiplatelet Effect AstraZeneca February 2009 Phase 1
NCT00688714 Completed Antiplatelet Effect AstraZeneca January 2008 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: AZD6482を買う | AZD6482 ic50 | AZD6482供給者 | AZD6482を購入する | AZD6482費用 | AZD6482生産者 | オーダーAZD6482 | AZD6482化学構造 | AZD6482分子量 | AZD6482代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID